Replies to post #538108 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Bob,

Keep in mind that BMY once sponsored a combo trial of dendritic cell with PD-1 inhibitor and the trial was terminated without success. I have no medical background. Intuitively I would think the key thing in using dendritic cells lies in how to educate them to recognize cancer cells better. I guess NWBO has unique value in this regard. That's why BMY came to NWBO for collaboration first and then later Merck.

https://clinicaltrials.gov/ct2/show/NCT02529072?cond=glioblastoma+%2B+Opdivo&draw=2&rank=20

[vator]

And the results from Liau’s presentation at Pitt was 50% cure rate. TEN times more than current SOC.

TEN times!!!!!!!

There is no way this is not becoming SOC as soon as approved. Oncologist will be combining ICIL or Keytruda with DCVax in record time.